EUCTR2014-005134-64-Outside-EU/EEA进行中（未招募）不适用
Phase I/II Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS-232632, ATAZANAVIR, ATV, REYATAZ™) in Combination Regimens in Antiretroviral Therapy (ART)-Naïve and Experienced HIV-Infected Infants, Children, and Adolescents - IMPAACT P1020A
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 195
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For step 1:
- •- Age: 91 days to 180 days of age.
- •- A confirmed diagnosis of HIV infection defined by the current definition of the IMPAACT Virology Core Laboratory Committee. The current (April 00) definition requires two separate peripheral blood specimens from different days, and each specimen must be positive. The two positive results may be obtained in any combination of the following:
- •at any age: HIV culture, HIV-DNA PCR, or Plasma HIV RNA value > 10,000 copies/mL
- •age >4 weeks: neutralizable HIV p24 antigen (regular or ICD)
- •age >18 months: licensed ELISA with confirmatory Western Blot
- •This definition may be updated by the IMPAACT Virology Core Laboratory Committee at any time. The IMPAACT P1020A will update the sites if these assays or their combination is modified. The protocol will always use the current definition of confirmed HIVinfection.
- •- Viral load = 5,000 copies/mL
- •- Any CDC clinical classification and immune status.
- •- Antiretroviral treatment naïve or experienced study candidates must be able to add two new NRTIs as part of their new therapy in this protocol, or have genotypic evidence of sensitivity to two NRTIs (the NRTIs must be used in combinations recommended in the Guidelines for the Use of Antiretroviral Agents in Pediatric and Adolescent HIV
- •Infection).
- •If the study candidate has previously received treatment with ddC, ddI will not be considered a new NRTI for his/her new regimen under this protocol, and vice-versa.
- •Abacavir sulfate (ABC, Ziagen®) and tenofovir disoproxil fumarate (TDF, Viread®) will be excluded as NRTI options for the subject’s regimen.
- •Sites must send an e-mail to the protocol team at actg.teamp1020@fstrf.org , establishing the candidate's PID#, date of
- •birth (DOB), and ART-history. This information is required to determine if genotypic testing is needed. Sites must receive
- •authorization, for each candidate, from the protocol team before proceeding with screening.
- •- Study candidates must show evidence of retained phenotypic sensitivity to BMS-232632 (resistance index ratio of less than 10) when the subject has failed (after at least 12 weeks of therapy) two or more courses of PI containing regimens.
- •Sites must send an e-mail to the protocol team at actg.teamp1020@fstrf.org , establishing the candidate's PID#, date of
- •birth (DOB), and ART-history. This information is required to determine if phenotypic testing is needed to confirm eligibility. Sites must receive authorization, for each candidate, from the protocol team before proceeding with screening.
- •- Demonstrated ability and willingness to swallow study medications.
- •- Study candidate, parent or legal guardian able and willing to provide signed informed consent.
- •- Female participants who are sexually active and able to become pregnant must use two methods of birth control. Hormonal birth control alone (e.g. pills, shots, or slow release inserts placed under the skin) would not be considered adequate. An effective, medically accepted barrier method of contraception [e.g., female/male condoms, diaphragm or cervical cap with a cream or gel that kills sperm, intrauterine device (IUD), others] must also be used during
- •the study. Condoms are recommended because their appropriate use is the only contraception method effective for preventing HIV transmission. Use of an IUD may increase the risk of pelvic inflammatory disease.
- •- Males participating in the study must not attempt to impregnate a female, or participate in sperm
排除标准
- •For Step 1:
- •- Active hepatitis.
- •- Presence of an acute serious/invasive infection requiring therapy at the time of enrollment.
- •- Hypersensitivity to any component of the formulation of BMS-232632.
- •- Chemotherapy for active malignancy.
- •- Pregnancy or breastfeeding.
- •- Any clinically significant diseases (other than HIV infection) or clinically significant findings during the screening medical history or physical examination that, in the clinician's opinion, would compromise the outcome of this study.
- •- Any laboratory or clinical toxicity > Grade 2 at entry
- •- Documented history of cardiac conduction abnormalities, or significant cardiac dysfunction.
- •- History of undefined syncope that can not be ruled out as related to cardiac conduction abnormalities6.
- •- Family history of prolonged QTc-interval syndrome, Brugada syndrome, or right-ventricular (RV) dyplasia.
- •- Corrected QTc-Interval > 440 msec at screening.
- •- Prolonged PR-Interval >0.200 seconds (200 ms) on ECG at screening (Study candidates =13 years of age).
- •- PR-Interval > 98th percentile on ECG at screening (Study candidates <13 years of age). Use Appendix VIII Table to Determine 98th Percentile for PR-Intervals in Subjects < 13 of Age”.
- •- Cardiac rhythm abnormalities:
- •A type I second-degree atrioventricular (AV) block (Mobitz type I heart-block) occurring during waking hours on ECG at
- •A type II second-degree AV-block (Mobitz type II heart-block) at any time on ECG at screening.
- •A complete AV-block at any time on ECG at screening.
- •A heart rate less than the 2nd percentile for age of the normal heart rate range (See Appendix IX) on ECG at screening.
- •- Prolonged therapy with intravenous pentamidine for acute Pneumocystis Carinii Pneumonia (PCP) within three months of entry.
- •For Step 2:
- •- A South African subject who meets any of the criteria for treatment discontinuation by Week 96 of the last subject enrolled into either part of Step I (see Section 6.4 Criteria for Treatment Discontinuation).
- •- A South African subject who meets any of the exclusion criteria (Section 4.2) from Step I by Week 96 of the last subject enrolled into either part of Step 1.
研究者
相似试验
招募中
不适用
A Phase I Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of CriPec® docetaxel in Patients with Solid Tumours.solid tumours / abnormal cell division in a particular organ10027655NL-OMON44828Cristal Therapeutics32
进行中（未招募）
1 期
A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Efficacy Study of Ascending Doses of Oral CK-101 in Patients with Advanced Solid TumorsEUCTR2017-001265-24-PLCheckpoint Therapeutics, Inc.122
进行中（未招募）
1 期
A Phase 1/2 Study of the Safety and Efficacy of CO-1686 in Patients with Previously Treated EGFR Non-Small Cell Lung CancerPreviously treated NSCLC patients who have documented evidence of an activating mutation in the EGFR gene and have failed treatment with an EGFR inhibitor such as erlotinib or gefitinibMedDRA version: 19.0 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS System Organ Class: 100000004864MedDRA version: 19.0 Level: LLT Classification code 10025048 Term: Lung cancer non-small cell recurrent System Organ Class: 100000004864EUCTR2011-005215-86-PLClovis Oncology, Inc.612
进行中（未招募）
1 期
A Phase I/II Study of Rucaparib, a PARP Inhibitor, in Patients with gBRCA Mutation Breast or Ovarian Cancer, or Other Solid TumorPatients with locally advanced or metastatic solid tumors who have progressed on standard therapy and patients with locally advanced or metastatic breast cancer with evidence of a germline mutation of BRCA1 or BRCA2 (gBRCA), and patients with platinum-sensitive relapsed ovarian cancer with evidence of a gBRCA mutation.MedDRA version: 14.1Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10006192Term: Breast cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10033130Term: Ovarian cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10025315Term: Lymphoma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-004250-26-ESClovis Oncology Inc.122
进行中（未招募）
1 期
A Phase I/II Study of Rucaparib, a PARP Inhibitor, in Patients with gBRCA Mutation Ovarian Cancer, or Other Solid TumorEUCTR2011-004250-26-GBClovis Oncology Inc.140